Attention-deficit drug linked to suicide risk

A DRUG used to treat attention-deficit hyperactivity disorder (ADHD) in children as young as six has been linked to a suicide risk, according to a warning from the state’s drug policing body.

The Irish Medicine Board (IMB) has posted a special alert on its website following a Europe-wide review of the risks and benefits of Atomoxetine that has been available in Ireland since January 2007.

The IMB said the review was conducted because of concern about the increased risk of suicidal thoughts and behaviour associated with the drug, also used to treat adolescents, as part of a comprehensive treatment programme.